We measured 2 types of biomarkers for each participant of the patient cohort in the discovery phase (consisted of 140 patients with NSCLC and 140 healthy controls): the CTC levels in blood and the expression levels of 5 mRNA biomarkers in saliva (i.e., CCNI, EGFR, FGF19, FRS2, and GREB1). This evidence concerns the gene FRS2 and non-small cell lung carcinoma.